论文部分内容阅读
目的评价奥卡西平(OXC)作为辅加药物治疗癫(Ⅰ组)以及单药治疗新诊断癫患者(Ⅱ组)在疗效、毒副作用方面的差异。方法Ⅰ组101例以OXC作为辅助添加剂治疗(OXC150～1200mg/d,中位数600mg/d),Ⅱ组23例以OXC作为单药治疗(OXC150～600mg/d,中位数450mg/d),随访3～25月;对2组患者治疗前后的发作频率、初始目标剂量、退出治疗情况、毒副作用进行对照分析或描述比较。结果Ⅰ、Ⅱ组发作控制率有非常显著性差异(P<0.01),两组总有效率无显著性差异(P>0.05);2组的初始目标剂量无显著性差异(P>0.05);2组因经济原因和毒副作用原因退出治疗的发生率无显著性差异(P>0.05),Ⅱ组的一般副作用发生率高于Ⅰ组(P<0.05)。结论OXC单药治疗国人新诊断的SPS,CPS,SGS的控制率优于作为辅加药物治疗癫,2组总有效率无显著性差异,初始目标剂量和退出治疗的发生率相近;OXC毒副作用相对较少、治疗范围大、用药和换药方便;在辅加治疗组患者对OXC的价格的承受力呈下降的趋势。
Objective To evaluate the difference in curative effect and toxic side effects of oxcarbazepine (OXC) as adjunctive drug in the treatment of epilepsy (group Ⅰ) and monotherapy in newly diagnosed epilepsy patients (group Ⅱ). In group Ⅰ, 101 patients were treated with OXC as auxiliary additive (OXC150 ~ 1200mg / d, median 600mg / d) and 23 patients in group Ⅱ were treated with OXC as single drug (OXC150 ~ 600mg / d, median 450mg / d) , Followed up for 3 to 25 months. The frequency of seizure, initial target dose, withdrawal treatment and side effects before and after treatment were compared or described and compared between the two groups. Results There was a significant difference in the control rate of seizure between the two groups (P <0.01). There was no significant difference in the total effective rate between the two groups (P> 0.05). There was no significant difference in the initial target dose between the two groups (P> 0.05). There were no significant differences in the incidence of withdrawal from treatment due to economic reasons and side effects (P> 0.05). The incidence of general side effects in group II was higher than that in group I (P <0.05). Conclusion OXC monotherapy in newly diagnosed Chinese SPS, CPS, SGS control rate is superior to as a supplementary drug treatment of epilepsy, total effective rate was no significant difference between the two groups, the initial target dose and exit the incidence of treatment was similar; OXC toxicity Side effects are relatively small, the treatment range, medication and dressing easy; patients in the adjuvant therapy group on the price of OXC downward trend in the affordability.